CDKN1A and cancer: Additionally, markers of cellular senescence CDKN2/p16ink4a and CDKN1A/p21 did not change between treatment groups in the RPPA analysis, while AXL, a known dormancy initiator in the context of PCa bone metastasis, increased in cancer cells treated with B-CM in the RPPA analysis.